<DOC>
	<DOCNO>NCT01753557</DOCNO>
	<brief_summary>This study evaluate efficacy safety MP-424 PEG-IFN Alfa-2a RBV patient genotype 1 hepatitis C , naïve treatment relapse previous treatment .</brief_summary>
	<brief_title>Efficacy Safety MP-424 , Peginterferon Alfa-2a ( PEG-IFN Alfa-2a ) , Ribavirin ( RBV ) Treatment-Naïve Relapsed Hepatitis C</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>Genotype 1 CHC treatmentnaïve relapsers ( patient relapse previous treatment ) Able willing follow contraception requirement Cirrhosis liver hepatic failure Hepatitis B surface antigenpositive HIV ( Human Immunodeficiency Virus ) antibodiespositive History , concurrent hepatocellular carcinoma History , concurrent depression , schizophrenia , suicide attempt past Pregnant , lactating , suspect pregnant patient , male patient whose female partner pregnant</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Pegasys</keyword>
</DOC>